Patents by Inventor Adrian Davis
Adrian Davis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240156797Abstract: A pharmaceutical composition can include a lipophilic oil. The pharmaceutical composition can further include an analgesic agent, anesthetic agent, anti-inflammatory agent, or a mixture thereof dispersed in the lipophilic oil. The pharmaceutical composition can further include a structuring agent at least a portion of which is not dissolved in the lipophilic oil and forms a gel.Type: ApplicationFiled: January 25, 2024Publication date: May 16, 2024Inventors: Brett Hale Davis, Caleb Adrian Lade, Sierra Nichelle Erickson, Susan Alice Wojtalewicz
-
Publication number: 20240091830Abstract: A decontamination apparatus for decontaminating an external surface is provided. The decontamination apparatus has a moveable platform and a containment structure mounted on the moveable platform. The containment structure has at least one aperture and a respective contact surface arranged around the perimeter of the aperture. The contact surface is arranged to make contact with the external surface to define a working volume, when the containment structure is positioned proximal to the external surface. The decontamination apparatus includes a decontamination device arranged to decontaminate the external surface. The decontamination device is arranged within the working volume and arranged to access the external surface through the at least one aperture. There is also a vacuum system for generating a partial vacuum in the containment structure to apply a suction force to the external surface.Type: ApplicationFiled: February 1, 2022Publication date: March 21, 2024Inventor: Adrian Davis-Johnston
-
Patent number: 11918572Abstract: A pharmaceutical composition can include a lipophilic oil. The pharmaceutical composition can further include an analgesic agent, anesthetic agent, anti-inflammatory agent, or a mixture thereof dispersed in the lipophilic oil. The pharmaceutical composition can further include a structuring agent at least a portion of which is not dissolved in the lipophilic oil and forms a gel.Type: GrantFiled: January 27, 2023Date of Patent: March 5, 2024Assignee: REBEL MEDICINE INCInventors: Brett Hale Davis, Caleb Adrian Lade, Sierra Nichelle Erickson, Susan Alice Wojtalewicz
-
Patent number: 11890294Abstract: The present invention provides a composition for topical administration of a polyhydroxy acid, such as lactobionate and especially zinc lactobionate, and low pH to an external body surface such as skin. The composition is designed to be highly effective in delivering low pH and zinc lactobionate across the layers of the skin to more effectively treat and prevent skin conditions involving a defective skin barrier such as eczema and severe dry skin.Type: GrantFiled: October 13, 2021Date of Patent: February 6, 2024Assignee: HYPHENS PHARMA PTE. LTD.Inventors: Kevin Hammond, Adrian Davis
-
Publication number: 20230330113Abstract: There is disclosed a composition for topical application of a cannabinoid as active ingredient comprising a solution of the cannabinoid in an excipient formulation comprising a polyhydric alcohol as partition coefficient enhancer, a saturated long-chain fatty acid or alcohol thereof as diffusion coefficient enhancer, and a co-solvent, wherein the saturated long-chain fatty acid or alcohol has a carbon chain length of from C10 to C16. The composition can be used in the treatment of a variety of conditions.Type: ApplicationFiled: April 12, 2021Publication date: October 19, 2023Inventor: Adrian DAVIS
-
Publication number: 20230210835Abstract: A composition for topical dermatological delivery of a medicinal or cosmeceutical or cosmetic active including a functional co-enhancer delivery system comprises a primary active agent in combination with an ancillary user adherence-improving skin barrier restoring system comprising nicotinamide and polyhydroxy acid. The composition generally comprises a water-miscible solvent and C12 or C14 fatty acids or C14 alcohol in combination with a hydrocarbyl methyl siloxane, other volatile silicones and a blend of silicone elastomers.Type: ApplicationFiled: June 21, 2021Publication date: July 6, 2023Inventor: Adrian Davis
-
Publication number: 20230022570Abstract: There is provided a composition for topical application to the penis for the treatment of erectile dysfunction, the composition being free of glyceryl trinitrate (GTN), sildenafil and an acetylcholinesterase inhibitor, and comprising volatile and non-volatile solvents, the volatile solvents comprising a lower alcohol and water and the non-volatile solvents comprising a polyhydric alcohol and a glycol. Preferably, the composition does not contain any pharmaceutically active ingredients for the treatment of erectile dysfunction. Also provided is a method of determining the cooling ability of a test composition, such as the composition described above.Type: ApplicationFiled: October 22, 2020Publication date: January 26, 2023Inventor: Adrian DAVIS
-
Patent number: 11376213Abstract: There is described a topical composition for application of an NSAID comprising ibuprofen, the composition comprising a solution or suspension of the NSAID as active ingredient in a residual carrier system comprising a polyhydric alcohol, a glycol ether, an ester of a higher fatty acid and optionally water, the ingredients of the residual carrier system having the following concentrations in percentages by weight: polyhydric alcohol 50-90 glycol ether 7.5-40 ester 0.5-5 water optional in which either the composition or the residual phase is in a single phase under ambient conditions and the maximum water concentration is that above which the composition or the residual phase exhibits signs of inhomogeneity.Type: GrantFiled: June 7, 2017Date of Patent: July 5, 2022Assignee: FUTURA MEDICAL DEVELOPMENTS LIMITEDInventors: Adrian Davis, Marc Barry Brown
-
Publication number: 20220031721Abstract: The present invention provides a composition for topical administration of a polyhydroxy acid, such as lactobionate and especially zinc lactobionate, and low pH to an external body surface such as skin. The composition is designed to be highly effective in delivering low pH and zinc lactobionate across the layers of the skin to more effectively treat and prevent skin conditions involving a defective skin barrier such as eczema and severe dry skin.Type: ApplicationFiled: October 13, 2021Publication date: February 3, 2022Applicant: HYPHENS PHARMA PTE. LTD.Inventors: Kevin HAMMOND, Adrian DAVIS
-
Patent number: 11173172Abstract: The present invention provides a composition for topical administration of a polyhydroxy acid, such as lactobionate and especially zinc lactobionate, and low pH to an external body surface such as skin. The composition is designed to be highly effective in delivering low pH and zinc lactobionate across the layers of the skin to more effectively treat and prevent skin conditions involving a defective skin barrier such as eczema and severe dry skin.Type: GrantFiled: May 10, 2018Date of Patent: November 16, 2021Assignee: HYPHENS PHARMA PTE. LTD.Inventors: Kevin Hammond, Adrian Davis
-
Publication number: 20210290081Abstract: A system for monitoring the exposure of a plurality of individuals to a physical or chemical property associated with an environment. The system includes a plurality of portable devices. Each portable device is arranged to be worn or carried by an individual in the environment. The system further includes a control unit for communicating with each of the plurality of portable devices. Each of the portable device includes a detector arranged to measure a physical or chemical property that the individual wearing or carrying the device is exposed to in the environment; one or more physiological sensors each arranged to measure a physiological parameter of the individual; a geolocation module arranged to determine the location of the individual; and a communication module for communicating data collected by the portable device with other(s) of the plurality of the portable devices and with the control unit.Type: ApplicationFiled: August 9, 2019Publication date: September 23, 2021Inventors: Dan Clifton-Climas, Adrian Davis-Johnston, Dominique Rothan, Anne-Marie Lissandre, Aurélien Ballier
-
Publication number: 20210000757Abstract: There is described a composition for topical application to the penis for treatment of erectile dysfunction, the composition comprising glyceryl trinitrate (GTN) as active ingredient dissolved in a blend of volatile and non-volatile solvents of different solvating capacities for the GTN, in which the volatile solvents comprise water and a lower alcohol and the non-volatile solvents comprise a polyhydric alcohol and a glycol having a ratio by weight of from 1.5:1 to 6.0:1, in which the composition has a pH as manufactured in the range 5.1 to 7.0. Also described is the use of the composition and methods involving the composition for treating or ameliorating erectile dysfunction.Type: ApplicationFiled: August 16, 2018Publication date: January 7, 2021Inventor: Adrian Davis
-
Patent number: 10828250Abstract: A formulation for topical dermatological delivery of a medicinal or cosmeceutical or cosmetic active including a functional co-enhancer delivery system. The delivery system generally comprises a water-miscible solvent and C12 or C14 fatty acids or C14 alcohol in combination with a hydrocarbyl methyl siloxane emollient.Type: GrantFiled: March 2, 2016Date of Patent: November 10, 2020Assignee: LIMEWAY PHARMA DESIGN LIMITEDInventor: Adrian Davis
-
Publication number: 20200222438Abstract: The present invention provides a composition for topical administration of a polyhydroxy acid, such as lactobionate and especially zinc lactobionate, and low pH to an external body surface such as skin. The composition is designed to be highly effective in delivering low pH and zinc lactobionate across the layers of the skin to more effectively treat and prevent skin conditions involving a defective skin barrier such as eczema and severe dry skin.Type: ApplicationFiled: May 10, 2015Publication date: July 16, 2020Applicant: HYPHENS PHARMA PTE. LTD.Inventors: Kevin HAMMOND, Adrian DAVIS
-
Publication number: 20190216721Abstract: There is described a topical composition for application of an NSAID comprising ibuprofen, the composition comprising a solution or suspension of the NSAID as active ingredient in a residual carrier system comprising a polyhydric alcohol, a glycol ether, an ester of a higher fatty acid and optionally water, the ingredients of the residual carrier system having the following concentrations in percentages by weight: polyhydric alcohol 50-90 glycol ether 7.5-40 ester 0.5-5 water optional in which either the composition or the residual phase is in a single phase under ambient conditions and the maximum water concentration is that above which the composition or the residual phase exhibits signs of inhomogeneity.Type: ApplicationFiled: June 7, 2017Publication date: July 18, 2019Inventors: Adrian Davis, Marc Barry Brown
-
Patent number: 10028927Abstract: Herein described is a topical composition for application of an NSAID, the composition comprising a solution or suspension of the NSAID as active ingredient in a residual carrier system comprising a polyhydric alcohol, a glycol ether, an ester of a higher fatty acid and water, and the ingredients of the residual carrier system have the following concentrations in percentages by weight::polyhydric alcohol 50-90%; glycol ether 7.5-40%; ester 0.5-5%; and water up to 10%. Either the composition or the residual carrier system is a single phase at ambient conditions. The composition may also comprise a volatile solvent such as ethanol or isopropyl alcohol.Type: GrantFiled: February 22, 2016Date of Patent: July 24, 2018Assignee: FUTURA MEDICAL DEVELOPMENTS LIMITEDInventor: Adrian Davis
-
Publication number: 20180036269Abstract: Herein described is a topical composition for application of an NSAID, the composition comprising a solution or suspension of the NSAID as active ingredient in a residual carrier system comprising a polyhydric alcohol, a glycol ether, an ester of a higher fatty acid and water, and the ingredients of the residual carrier system have the following concentrations in percentages by weight::polyhydric alcohol 50-90%; glycol ether 7.5-40%; ester 0.5-5%; and water up to 10%. Either the composition or the residual carrier system is a single phase at ambient conditions. The composition may also comprise a volatile solvent such as ethanol or isopropyl alcohol.Type: ApplicationFiled: February 22, 2016Publication date: February 8, 2018Applicant: Futura Medical Developments LimitedInventor: Adrian DAVIS
-
Publication number: 20180028438Abstract: A formulation for topical dermatological delivery of a medicinal or cosmeceutical or cosmetic active including a functional co-enhancer delivery system. The delivery system generally comprises a water-miscible solvent and C12 or C14 fatty acids or C14 alcohol in combination with a hydrocarbyl methyl siloxane emollient.Type: ApplicationFiled: March 2, 2016Publication date: February 1, 2018Inventor: Adrian Davis
-
Publication number: 20170020898Abstract: There is provided a topical pharmaceutical composition comprising the following components and percentages: ester of salicylic or nicotinic acid—10-20%; menthol—5-10%; lower alcohol—15-35%; water—10-20%; propylene glycol and/or pentane-1,5-diol—15-35%; hydrophilic pharmaceutically-acceptable non-volatile non-solvent for menthol—2-16%; and, optionally, up to 5% camphor, all percentages being by weight. Also provided is a topical pharmaceutical composition comprising a volatile phase and a non-volatile phase, the non-volatile phase comprising from 32-81% of the total composition by weight, and comprising the following non-volatile constituents, expressed as % weight of the non-volatile phase: ester of salicylic or nicotinic acid—14-48%; menthol—7-27%; propylene glycol and/or pentane-1,5-diol—25-67%; hydrophilic pharmaceutically-acceptable non-volatile non-solvent for menthol—3-35%, and a concentrate comprising the non-volatile components of this composition.Type: ApplicationFiled: November 27, 2014Publication date: January 26, 2017Inventor: Adrian DAVIS
-
Publication number: 20130028986Abstract: A composition comprising a pharmaceutically acceptable group (2, 4, 12, 13 or 14) metal compound for the treatment of a dermatological condition involving an abnormal decrease in the cell-to-cell adhesion between epithelial cells in the epidermal barrier.Type: ApplicationFiled: August 7, 2012Publication date: January 31, 2013Applicant: SABAREP LIMITEDInventors: Simon Ward, Alice MacGowan, Michael J. Cork, Jonathan Hadgraft, Majella Lane, Adrian Davis, Richard Guy